Clinical trials: Neoplasms by Site
Locally Advanced or Metastatic Urothelial Cell Carcinoma, Urinary Bladder Disease
A Study of B-701 in Combination With Pembrolizumab in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma
This is a Phase 1b/2 multi-center, open-label study to establish the initial safety and to determine a recommended Phase 2 dose of B-701 in combination with pembrolizumab, and to determine safety, tolerability and efficacy of…
- Conditions
- Locally Advanced or Metastatic Urothelial Cell Carcinoma, Urinary Bladder Disease, Urological Diseases
- Trial name
- FIERCE-22 (NCT03123055)
- Testing
- B-701, Pembrolizumab
- Where
- 52 sites in United States, Belgium and 15 more
- Volunteers
- 28 people
- Sponsor
- Rainier Therapeutics
Non-small Cell Lung Cancer
Clinical Trial in Chinese Healthy Volunteers of GB222
The primary objective of this study is to evaluate the similarity of the primary pharmacokinetic (PK) parameter AUC0-t of GB222 and bevacizumab after single administration; the secondary objective is to observe the safety and…
- Trial name
- NCT04175158
- Testing
- GB222, Bevacizumab
- Where
- China
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Genor Biopharma Co., Ltd.
Lung Neoplasm
Evaluation of the LungPoint Virtual Bronchoscopic Navigation (VBN) System
To evaluate the role of the LungPoint VBN System in the bronchoscopic access to a target location. The evaluation will explore: Ability of the system to guide a user to one or more target site(s) Ease of use of the system…
- Trial name
- NCT01067755
- Testing
- LungPoint Virtual Bronchoscopic Navigation (computer-assisted image-guided bronchoscopic navigation)
- Where
- Germany
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Broncus Technologies
Breast Cancer
Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment
The goal of this clinical trial is to learn if tinengotinib combined with fulvestrant works to treat patients with HR-Positive and HER-2-Negative or low-expressing advanced breast cancer.
- Trial name
- NCT07498478
- Testing
- Tinengotinib at the optimal dose combined with Fulvestrant, Tinengotinib, tinengotinib combined with fulvestrant
- Where
- 13 sites in China
- Volunteers
- 94 people
- Sponsor
- TransThera Sciences (Nanjing), Inc.
Endometrial Carcinoma, Ovarian Carcinoma
Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)
This trial is a Phase 1b/2a/3 trial designed to evaluate the safety and efficacy of adding oral AL3818 (Anlotinib, INN: Catequentinib), a Dual Receptor Tyrosine Kinase Inhibitor, to standard platinum-based chemotherapy…
- Conditions
- Endometrial Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
- Trial name
- AL3818 (NCT02584478)
- Testing
- AL3818, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD)
- Where
- 41 sites in United States, China and 4 more
- Volunteers
- 294 people
- Sponsor
- Advenchen Laboratories, LLC
NUT Midline Carcinoma (NMC), Triple Negative Breast Cancer (TNBC)
A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006)
This is a study to determine the recommended dose of birabresib (MK-8628)(formerly known as OTX015) for further studies in participants with advanced nuclear protein in testis (NUT) midline carcinoma (NMC), triple negative breast…
- Conditions
- NUT Midline Carcinoma (NMC), Triple Negative Breast Cancer (TNBC), Non-small Cell Lung Cancer (NSCLC), Castration-resistant Prostate Cancer (CRPC)
- Trial name
- NCT02698176
- Testing
- Birabresib
- Volunteers
- 13 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Solid Tumors, Genital Neoplasm, Female
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent and in combination with chemotherapy administered intravenously in participants…
- Conditions
- Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm
- Trial name
- START-001 (NCT05592626)
- Testing
- STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere)
- Where
- 19 sites in United States, Canada and 2 more
- Volunteers
- 366 people
- Sponsor
- Marengo Therapeutics, Inc.
Colorectal Cancer
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Study BT-CL-PGG-CRC1031 is a Phase 3, open-label, randomized, multi-center study. Qualified subjects, who have KRAS wild type (WT) colorectal cancer will be randomized in a 2:1 ratio to treatment with either Imprime PGG and…
- Trial name
- PRIMUS (NCT01309126)
- Testing
- Imprime PGG + cetuximab, Cetuximab
- Where
- 53 sites in United States, France and 2 more
- Volunteers
- 217 people
- Sponsor
- HiberCell, Inc.
Breast Cancer
Safety and Efficacy of Hormone Therapy With Letrozole in Postmenopausal Women With Breast Cancer
The aim of this study is to assess the safety and efficacy of neoadjuvant hormone therapy with letrozole in postmenopausal women with estrogen- and/or progesterone-receptor positive primary breast cancer on tumour regression to…
- Trial name
- NCT00330317
- Testing
- letrozole
- Where
- 20 sites in United Kingdom
- Volunteers
- 300 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Pancreatic Cancer
Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer
This clinical trial is an open label Phase II study of the combination of intravenously administered SGT-53 and gemcitabine/nab-paclitaxel in patients with metastatic pancreatic cancer.
- Trial name
- NCT02340117
- Testing
- SGT-53, nab-paclitaxel, Gemcitabine
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- SynerGene Therapeutics, Inc.
Metastatic Colorectal Cancer
A Post-Marketing Surveillance Study On Erbitux® (Cetuximab) In Patients With Metastatic Colorectal Cancer Refractory To Irinotecan Containing Treatment
A post marketing surveillance, prospective study to collect safety information from 250 subjects with epidermal growth factor receptor (EGFR) expressing, KRAS wild-type metastatic colorectal cancer treated with Erbitux as final…
- Trial name
- NCT01134640
- Where
- 15 sites in Taiwan
- Volunteers
- 286 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Pancreatic Cancer, Neoplasm Metastasis
Trial of Talabostat and Gemcitabine in Patients With Stage IV Adenocarcinoma of the Pancreas
The purpose of this study is to assess the 6-month survival rate and safety of talabostat and gemcitabine in patients with stage IV adenocarcinoma of the pancreas.
- Conditions
- Pancreatic Cancer, Neoplasm Metastasis, Adenocarcinoma
- Trial name
- NCT00116389
- Testing
- talabostat mesylate tablets, gemcitabine
- Where
- 28 sites in United States
- Volunteers
- 60 people
- Sponsor
- Point Therapeutics
Advanced Solid Tumor, Colorectal Cancer
First in Human Study of TORL-3-600 in Participants With Advanced Cancer
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-3-600 in patients with advanced cancer
- Trial name
- NCT05948826
- Testing
- TORL-3-600
- Where
- 9 sites in United States, Canada
- Volunteers
- 70 people
- Sponsor
- TORL Biotherapeutics, LLC
Unresectable Melanoma, Metastatic Melanoma
A Study to Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Unresectable or Metastatic Melanoma Participants In India
The purpose of this study is to assess the safety and tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) in unresectable or metastatic melanoma participants in India.
- Trial name
- NCT07459543
- Testing
- Nivolumab + Relatlimab
- Where
- 11 sites in India
- Volunteers
- 40 people
- Sponsor
- Bristol-Myers Squibb
Colon Cancer, Gastrointestinal Cancer
Seal-G / Seal-G MIST Study
A prospective, multi-center, open label, study to evaluate safety and performance of Seal-G and Seal-G MIST in reinforcing colonic anastomosis, in subjects undergoing Colon Resection surgery
- Trial name
- NCT04532515
- Testing
- Seal-G Surgical Sealant, Seal-G MIST System
- Where
- 2 sites in Israel
- Volunteers
- 160 people
- Sponsor
- Advanced Medical Solutions Ltd.
Kidney Cancer, Renal Cancer
Safety and Effectiveness of Nivolumab in Recurring Kidney Cancer Participants
A non-interventional, medical record review of clinical data collected from Japanese participants with recurring kidney cancer
- Trial name
- NCT03568435
- Testing
- Non-Interventional
- Where
- Japan
- Volunteers
- 212 people
- Sponsor
- Bristol-Myers Squibb
Prostate Cancer
A Phase II Trial of TPI 287 in Patients With Metastatic Prostate Cancer
The primary objective of the study is to determine the response rate to TPI 287 in patients with metastatic, hormone-refractory prostate cancer who have had one prior taxane regimen.
- Trial name
- NCT00479635
- Testing
- TPI 287
- Where
- 6 sites in United States
- Volunteers
- 26 people
- Sponsor
- Cortice Biosciences, Inc.
Cervical Cancer, Cancer
A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human Papillomavirus (HPV)+ Head & Neck Cancer
This was a multicenter, open-label, 2-part randomized study of MEDI4736 administered as monotherapy or in combination with ADXS11-001 to participants with recurrent/persistent or metastatic squamous or non-squamous carcinoma of…
- Conditions
- Cervical Cancer, Cancer, Head and Neck Cancer
- Trial name
- NCT02291055
- Testing
- ADXS11-001, MEDI4736
- Where
- 17 sites in United States
- Volunteers
- 75 people
- Sponsor
- Advaxis, Inc.
Breast Cancer, Advanced Breast Cancer
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer
The reason for this study is to see if the study drug LY3484356 alone or in combination with other anticancer therapies is safe and effective in participants with advanced or metastatic breast cancer or endometrial cancer.
- Conditions
- Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, Endometrial Cancer
- Trial name
- EMBER (NCT04188548)
- Testing
- LY3484356, Abemaciclib, Everolimus
- Where
- 74 sites in United States, Australia and 6 more
- Volunteers
- 379 people
- Sponsor
- Eli Lilly and Company
Stage IV Non-small Cell Lung Cancer
KN046 in Patients With Advanced Non-small Cell Lung Cancer
This is a phase II, open label, multicenter study in subjects with advanced non-small cell lung cancer.
- Trial name
- NCT03838848
- Testing
- KN046, Carboplatin, Pemetrexed
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.